Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
TAK-500 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting an undisclosed tumor-associated antigen and the STING agonist TAK-676, which may result in increased STING pathway activation and anti-tumor immune response (NCI Drug Dictionary).
|DrugClasses||STING1 Agonist 19|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Pembrolizumab + TAK-500||Pembrolizumab TAK-500||0||1|